El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

249341.pdf (12.7 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-02-22

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207366

Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1172/JCI148667

Resum

The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.

Matèries

Càncer de mama, Tumors, Cèl·lules canceroses

Matèries (anglès)

Breast cancer, Tumors, Cancer cells

Citació

Col·leccions

Articles publicats en revistes (Biomedicina)

Citació

ARAUJO, Ángela m., ABAURREA, Andrea, AZCOAGA, Peio, LÓPEZ VELAZCO, Joanna i., MANZANO, Sara, RODRÍGUEZ, Javier, REZOLA, Ricardo, EGIA MENDIKUTE, Leire, VALDÉS MORA, Fátima, FLORES, Juana m., JENKINS, Liam, PULIDO, Laura, OSORIO QUEREJETA, Iñaki, FERNANDEZ-NOGUEIRA, Patricia, FERRARI, Nicola, VIERA, Cristina, MARTIN MARTIN, Natalia, TZANKOV, Alexandar, EPPENBERGER CASTORI, Serenella, ALVAREZ LOPEZ, Isabel manuela, URRUTICOECHEA RIBATE, Ander, BRAGADO DOMINGO, Paloma, COLEMAN, Nicholas, PALAZÓN, Asis, CARRACEDO, Arkaitz, GALLEGO ORTEGA, David, CALVO, Fernando, ISACKE, Clare m., CAFFAREL, María m., LAWRIE, Charles h.. Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment. _Journal of Clinical Investigation_. 2022. Vol. 132, núm. 19. [consulta: 29 de desembre de 2025]. ISSN: 0021-9738. [Disponible a: https://hdl.handle.net/2445/207366]

Exportar metadades

JSON - METS

Compartir registre